<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01757470</url>
  </required_header>
  <id_info>
    <org_study_id>D4200L00059</org_study_id>
    <nct_id>NCT01757470</nct_id>
  </id_info>
  <brief_title>Vandetanib Risk Minimisation Effectiveness</brief_title>
  <official_title>Effectiveness of Risk Minimisation Interventions for Vandetanib in Canada</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Effectiveness of risk minimisation interventions for vandetanib in Canada
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As part of the new drug approval process in Canada, AstraZeneca has committed to Health
      Canada to conduct a Drug Utilization Study among patients recently treated with CAPRELSA
      (vandetanib) and a Knowledge and Understanding Survey among the prescribing physicians to
      determine whether the product monograph, communication plan, and educational material
      developed by AstraZeneca Canada for vandetanib are adequate to provide knowledge about the
      potential risks associated with this product, and if other medications taken concomitantly
      with vandetanib are managed adequately.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Knowledge and Understanding Survey: Knowledge of the key safety issues pertaining to vandetanib</measure>
    <time_frame>2 months</time_frame>
    <description>QT prolongation/TdP Torsades, diarrhea, rash and other skin reactions- adequate or inadequate for each safety issue (defined by correct response).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug Utilisation Study: Use of vandetanib - duration of treatment at baseline</measure>
    <time_frame>At baseline</time_frame>
    <description>Discontinuation, interruption, continuous</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug Utilisation Study: Use of vandetanib - duration of treatment at 3 months</measure>
    <time_frame>At 3 months</time_frame>
    <description>Discontinuation, interruption, continuous</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug Utilisation Study: Use of vandetanib - duration of treatment at 6 months</measure>
    <time_frame>At 6 months</time_frame>
    <description>Discontinuation, interruption, continuous</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug Utilisation Study: Use of vandetanib - duration of treatment at 12 months</measure>
    <time_frame>At 12 months</time_frame>
    <description>Discontinuation, interruption, continuous</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug Utilisation Study: Use of vandetanib - dosage at baseline</measure>
    <time_frame>At baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug Utilisation Study: Use of vandetanib - dosage at 3 months</measure>
    <time_frame>At 3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug Utilisation Study: Use of vandetanib - dosage at 6 months</measure>
    <time_frame>At 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug Utilisation Study: Use of vandetanib - dosage at 12 months</measure>
    <time_frame>At 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug Utilisation Study: Concomitant use of QT-prolonging drugs at baseline</measure>
    <time_frame>At baseline</time_frame>
    <description>Dichotomous variable - yes/no + total number of concomitant QT-prolonging drugs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug Utilisation Study: Concomitant use of QT-prolonging drugs at 3 months</measure>
    <time_frame>At 3 months</time_frame>
    <description>Dichotomous variable - yes/no + total number of concomitant QT-prolonging drugs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug Utilisation Study: Concomitant use of QT-prolonging drugs at 6 months</measure>
    <time_frame>At 6 months</time_frame>
    <description>Dichotomous variable - yes/no + total number of concomitant QT-prolonging drugs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug Utilisation Study: Concomitant use of QT-prolonging drugs at 12 months</measure>
    <time_frame>At 12 months</time_frame>
    <description>Dichotomous variable - yes/no + total number of concomitant QT-prolonging drugs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Knowledge and Understanding Survey: Practice characteristics</measure>
    <time_frame>2 months</time_frame>
    <description>Main geographical location, average days devoted to patient care, total number of medullary thyroid cancer patients followed up to date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knowledge and Understanding Survey: Previous exposure to vandetanib safety concerns other than product monograph or mandatory online training</measure>
    <time_frame>2 months</time_frame>
    <description>Participation in a trial on vandetanib, giving CME conferences, member of a data safety monitoring board.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knowledge and Understanding Survey: Sources of information on key safety messages for vandetanib</measure>
    <time_frame>2 months</time_frame>
    <description>Product monograph, online training, Dear Healthcare Professional letter sent by AstraZeneca, company's sales forces, continuing medical education, conferences.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">12</enrollment>
  <condition>Medullary Thyroid Cancer</condition>
  <arm_group>
    <arm_group_label>Caprelsa Patient</arm_group_label>
    <description>All patients treated with Caprelsa in Canada and participating in the restricted distribution programme.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Caprelsa Prescriber</arm_group_label>
    <description>All physicians having prescribed at least one dose of Caprelsa and registered as a certified prescriber of Caprelsa in Canada.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Convenience sample for patients and physicians
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - N/A (all patients taking Caprelsa and all prescribers will be contacted for
        participation).

        Exclusion Criteria: - N/A
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2012</study_first_submitted>
  <study_first_submitted_qc>December 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2012</study_first_posted>
  <last_update_submitted>August 30, 2016</last_update_submitted>
  <last_update_submitted_qc>August 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>effectiveness of risk mitigation,</keyword>
  <keyword>knowledge and understanding survey,</keyword>
  <keyword>drug utilisation study,</keyword>
  <keyword>post marketing commitments</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Neuroendocrine</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

